Acitretin has been shown to increase ADAM10 expression. In a phase II clinical trial, Alzheimer's disease patients were treated with acitretin or placebo to increase ADAM10 levels to counteract amyloid beta production. Analysis of the cerebrospinal fluid of from 18 AD patients treated with the synthetic retinoid acitretin or placebo were analyzed by label-free quantitative LC-MS/MS analysis.
[dataset license: CC0 1.0 Universal (CC0 1.0)]
Keywords: Alzheimer disease ; Csf ; Acitretin ; DatasetType:Proteomics
|
Principal Investigators: (in alphabetical order) |
Stefan F. Lichtenthaler, DZNE Munich Neuroproteomics Feodor-Lynen Str. 17 81377 Munich Germany, N/A |
| Submitting User: | ccms |
| Number of Files: | |
| Total Size: | |
| Spectra: | |
| Subscribers: | |
| Owner | Reanalyses | |
|---|---|---|
| Experimental Design | ||
|
Conditions:
|
||
|
Biological Replicates:
|
||
|
Technical Replicates:
|
||
| Identification Results | ||
|
Proteins (Human, Remapped):
|
||
|
Proteins (Reported):
|
||
|
Peptides:
|
||
|
Variant Peptides:
|
||
|
PSMs:
|
||
| Quantification Results | ||
|
Differential Proteins:
|
||
|
Quantified Proteins:
|
||
| Browse Dataset Files | |
|
FTP Download Link (click to copy):
|